Evaluate Efficacy of the Association Nimotuzumab(HR3) /Cisplatin-Vinorelbine on Patients With Cervical Carcinom

Inclusion Criteria: * Patients aged between 18 to 75, including both limits. * Patients who give their written consent to participate to the study. * Chemonaive patients with local cervical cancer and / or persistent or recurrent metastatic disease with measurable disease (RECIST criteria) by a physical examination (scanner or MRI). A confirmation by biopsy is necessary in case there is a single lesion less than 2 cm. * Patients who had pelvic CT + radiotherapy may also be included in the study (concomitant chemotherapy as a radiotherapy stabilizer). * Patients having a histopathological report: epidermoid carcinoma, adenocarcinoma, adenosquamous carcinoma and / or clear cells carcinoma. * Patients with an ECOG score between 0-2 * Patients with a life expectancy greater than six months. * Patients with Left Ventricular Ejection Fraction (LVEF) ≥50%, through Echocardiography. * Patients with normal function of organs and bone marrow, defined by the following parameters: * Haemoglobin ≥ 9 g / dL * White Blood cell ≥ 4000 /mm3 * Absolute neutrophil count≥ 1500 /mm3 * Platelet count≥ 100000 /mm3 * Total bilirubin up to 1.5 the upper limit of normal (ULN) * Albumin ≥ 2 g/dL (3,5 - 5,0 g /dl) * Serum Glutamopyruvate Transférase (SGPT) and SErum Glutamooxaloacetate Transferase (SGTO) \< or = 2.5 ULN * Serum creatinine within the normal limits and the calculation of glomerular filtration according to Cockcroft formula ≥ 60ml and according to MDRD formula for patients whose age is 70 years ≥ 60ml . Glomerular filtration will be performed only on clinical discretion for patients suspected to have a kidney problem. (The normal laboratory values will be appropriate to the techniques and equipment used in the place where they are done). * The determination or expression of EGF-R (epidermal growth factor receptor), p53, Ki67 and Bcl-2 by immuno-histochemistry in the primary tumor before treatment integrated in a paraffin block. The results are not an inclusion criterion, but will be evaluated as an indicator of prognostic response in the final assessment. Exclusion Criteria: * Pregnant or breastfeeding patients * Patients with small cells and / or neuroendocrine cervical cancer. * Patients receiving another onco-specific drug, for other clinical trial, * Patients with a history of allergy attributed to chemical or biological compounds similar to the monoclonal antibody being evaluated or to chemotherapeutic agents. * Patients having uncontrolled intercurrent diseases, including active infections, symptomatic congestive heart failure , unstable angina, cardiac arrhythmia, decompensated diabetes, uncontrolled hypertension and psychiatric disorders. * Patients having a second tumor . Excepting for those receiving appropriate therapy for skin cancer (basal or squamous) * Previous or concomitant malignancy with exception for non-melanoma skin carcinomas * Patients having special conditions or circumstances that could significantly limit the complete follow up of the study